Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505049 | 0.85 | GRM5 (1.00) | GRM5CLK4CA12CA9 | |
| SCHEMBL504639 | 0.82 | GRM5 (0.76) | GRM5DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL504344 | 0.81 | GRM5 (0.81) | GRM5PARP10PARP11DAPK3NTRK1 | |
| SCHEMBL30545957 | 0.78 | GRM5 (0.68) | GRM5PARP10PARP11DAPK3NTRK1 | |
| SCHEMBL164795 | 0.78 | GRM5 (0.68) | GRM5PARP10PARP11DAPK3NTRK1 | |
| SCHEMBL10243599 | 0.78 | PARP10 (0.74) | GRM5PARP10PARP11DAPK3NTRK1 | |
| SCHEMBL24570503 | 0.77 | GRM5 (0.72) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL29739073 | 0.77 | GRM5 (0.72) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL504655 | 0.74 | GRM5 (0.82) | GRM5PARP10PARP11 | |
| SCHEMBL2021324 | 0.73 | GRM5 (0.64) | GRM5DAPK3NTRK1PIM1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-8034806-B2 | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034806-B2 | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2162136-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885PARP10 2146/4885PARP11 3085/4885 |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885PARP10 2146/4885PARP11 3085/4885 |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885PARP10 2146/4885PARP11 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.